2020
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum
Noureddin M, Chan J, Barradas K, Dimick-Santos L, Schabel E, Omokaro S, Anania F, Myers R, Miller V, Sanyal A, Chalasani N, Group L, Anania F, Bajaj J, Barradas K, Berzigotti A, Birman P, Bosch J, Brower A, Calboli D, Chalasani N, Chan J, Charlton W, Dickinson K, Dimick-Santos L, Filozof C, Forsgren M, Fuchs M, Garcia-Tsao G, Gonzalez-Abraldes J, Gruss H, Hansen M, Hosman S, Imperial J, Jones D, Lalazar G, Leinhard O, Lyons E, McColgan B, Mehta R, Mesenbrink P, Miller V, Myers R, Noureddin M, Omokaro S, Pei V, Ratziu V, Regev A, Riccio R, Sanyal A, Schabel E, Seo S, Smith A, Szitanyi P, Traber P. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology 2020, 159: 422-427.e1. PMID: 32353369, DOI: 10.1053/j.gastro.2020.04.039.Commentaries, Editorials and LettersConceptsEtiology of cirrhosisClinical trial eligibilityTrial eligibilityNonalcoholic steatohepatitisCirrhosisSteatohepatitisEtiology
2019
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Garcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.Peer-Reviewed Original ResearchConceptsSevere portal hypertensionPortal hypertensionAlanine aminotransferaseCompensated cirrhosisEnd-stage liver disease (MELD) scoreAspartate aminotransferaseAST/alanine aminotransferaseChild class ALiver Disease scoreOpen-label studyNonserious adverse eventsPortal venous inflowAnti-inflammatory effectsHepatitis C virusSplanchnic vasodilationAdverse eventsHVPG measurementIntrahepatic inflammationPortal pressureBlood pressureCirrhosis etiologyMedian ageNonalcoholic steatohepatitisVenous inflowSignificant changes